randomized clinical

Related by string. * Randomized . randomizing . randomizer : randomized controlled trial . randomized controlled trials / clinicals . CLINICAL : Phase III clinical trials . Phase III clinical * randomized clinical trials . Randomized Clinical Trial . multicenter randomized clinical . Randomized clinical trials . ARTISTIC randomized clinical . Randomized Clinical Trials *

Related by context. All words. (Click for frequent words.) 83 randomized controlled 81 randomized controlled trial 80 prospective randomized 79 randomized placebo controlled 78 multicenter 78 randomized controlled clinical 77 randomized 76 placebo controlled 75 multicenter study 75 prospective randomized controlled 74 multicenter randomized 74 multicenter clinical 73 randomized trials 73 placebo controlled clinical 72 randomized clinical trials 72 randomized Phase III 72 observational study 71 multicentre 71 nonrandomized 70 randomized blinded 70 randomized double 70 randomized controlled trials 70 double blind placebo 70 placebo controlled randomized 70 double blinded randomized 70 blind randomized placebo 70 clinical trial 70 multicentre randomized 70 prospective multicenter 70 blind randomized 69 prospective observational 69 randomized multicenter 68 multicenter prospective 68 multicenter randomized controlled 68 prospective cohort 68 Phase III randomized 67 phase IIb clinical 67 ONTARGET 67 placebo controlled Phase 67 multicenter randomized clinical 67 double blinded placebo 67 randomized controlled clinical trials 66 blinded randomized 66 substudy 66 multicentre randomized double 66 placebo controlled studies 65 randomized Phase IIb 65 blind randomized controlled 65 blinded placebo controlled 65 randomized multicenter trial 65 phase IIa clinical 65 multicenter Phase II 65 SPIRIT III 65 multicenter randomized double 65 placebo controlled trials 65 RE LY ® 65 subanalysis 65 phase IIb 65 placebo controlled Phase III 65 phase IIa 64 retrospective cohort study 64 Phase III clinical 64 EVEREST II 64 Phase 2b study 64 active comparator 64 prospective randomized placebo 64 blind placebo controlled 64 controlled multicenter 64 meta analysis 64 multicenter trials 64 subgroup analyzes 64 Phase 1b clinical 64 Phase IIb trial 64 trials RCTs 64 multicentre study 63 blinded randomized controlled 63 Phase Ib clinical 63 observational studies 63 prospective randomized multicenter 63 Randomized controlled 63 dose escalation study 63 RE LY 63 Carotid Revascularization Endarterectomy vs. 63 masked placebo controlled 63 Phase 2a clinical 63 dose escalation trial 63 Prostate Lung Colorectal 63 Phase Ib 63 Phase IIb 63 confirmatory clinical 63 multicenter randomized placebo controlled 62 NO# [002] 62 dose dose escalation 62 Phase IIIb clinical 62 longitudinal cohort study 62 Phase 1b trial 62 Intervention Effectiveness 62 Phase IIIb 62 label multicenter 62 prospective nonrandomized 62 Phase IIB 62 DAPT 62 Phase IIb clinical 62 randomized crossover 62 dose escalation Phase 62 Phase 2b clinical 62 multicenter placebo controlled 62 placebo controlled clinical trials 62 phase IIIb 62 Phase 2a trial 62 prospectively randomized 62 Prostate Cancer Prevention 62 TAXUS ATLAS 62 dose escalation clinical 62 retrospective observational study 62 AIM HIGH 61 viral kinetic 61 Phase IIIb study 61 longitudinal study 61 prospective multicenter randomized 61 SPIRIT IV 61 ABSORB trial 61 multicenter Phase 61 EchoCRT 61 paclitaxel eluting stents 61 TG MV 61 clinical trials 61 HeFT 61 phase Ib 61 MADIT II 61 Edge STudy 61 Clinical Antipsychotic Trials 61 multicenter phase 61 BRIM3 61 Phase Ia 61 VADT 61 BARI 2D 61 ExTRACT TIMI 61 randomized Phase 61 postmenopausal women 61 multicenter multinational 61 HCV SPRINT 60 dose escalation 60 ADVANCE PD 60 nab paclitaxel 60 Randomized 60 TMC# C# 60 Health Initiative WHI 60 HPTN 60 ALLHAT 60 dabigatran etexilate 60 noninferiority 60 retrospective cohort 60 phase IIb trial 60 analgesic efficacy 60 Randomized Evaluation 60 liver transplant recipients 60 landmark ATHENA 60 oral rivaroxaban 60 PRoFESS 60 Phase 2b trial 59 multicenter Phase III 59 PRECiSE 59 REALITY Trial 59 recurrent malignant glioma 59 PFO migraine 59 pharmacokinetics PK 59 ENDEAVOR IV 59 phase III ACCLAIM 59 ACTIVE W 59 randomized blinded placebo 59 Ovarian Cancer Screening 59 randomized multicentre 59 Multicenter 59 single ascending dose 59 RSD# oral 59 Phase Ib II 59 label dose escalation 59 neoadjuvant 59 Phase 1b 59 recurrent GBM 59 blind multicenter 59 Phase III randomized controlled 59 Phase III 59 BOLDER II 59 Sorafenib HCC Assessment 59 Phase III VISTA 59 pharmacodynamics 59 HOPE TOO 59 LUX Lung 59 Phase IIa 59 everolimus eluting stents 59 CARE HF 59 riociguat 59 NEVO RES 59 ASTEROID 59 eptifibatide 59 SPARCL 59 ascending dose 59 sunitinib malate 59 Randomised 59 rFVIIa 59 blinded randomized placebo controlled 59 Val HeFT 59 Phase IIa trial 59 Phase IIa clinical 59 Betaferon ® 59 TAXUS VI 58 CYPHER R Sirolimus eluting 58 Intervention Trial 58 AVERROES 58 longitudinal studies 58 chemoradiotherapy 58 prospective longitudinal 58 AIR CF1 58 NICE SUGAR 58 HF ACTION 58 pivotal Phase III 58 Phase 1a 58 phase 2a 58 RCTs 58 GISSI HF 58 Stenting Trial CREST 58 VITAL Trial 58 ACUITY trial 58 Phase III pivotal 58 CALGB 58 randomized multicenter Phase III 58 BRIM2 58 APTIVUS 58 RE LY trial 58 ATACAND 58 prospectively defined 58 ATTRACT 58 MIST II 58 metastatic HRPC 58 placebo controlled dose escalation 58 rosuvastatin 58 multicentre randomized controlled 58 ticagrelor 58 TAXUS IV 58 ACCOMPLISH 58 SWOG 58 Phase 2b 58 symptomatic BPH 58 Cholesterol Levels SPARCL 58 clinical pharmacology studies 58 blind placebo 58 MEND CABG 58 Phase IIb III 58 randomized #:# 58 non inferiority 58 adalimumab 58 lipid lowering therapy 58 RRMS patients 58 carotid artery stenting 58 EFAPROXYN 58 meta analyzes 58 unblinding 58 eculizumab 58 everolimus eluting stent 58 Multi Ethnic Study 58 LCP AtorFen 57 teriflunomide 57 Atherosclerosis MESA 57 Ovarian PLCO Cancer 57 Aggressive Reduction 57 NCCTG 57 EURIDIS 57 NSABP B 57 Communities ARIC study 57 Intervention Effectiveness CATIE 57 tiotropium 57 ASCEND HF 57 HORIZONS AMI trial 57 IMPROVE HF 57 pivotal bioequivalence 57 MERLIN TIMI 57 statin therapy 57 Endovascular Valve Edge 57 NCT# ClinicalTrials.gov 57 CHAMPION PCI 57 UKPDS 57 epidemiologic studies 57 ECASS 57 STRIDE PD 57 AIR CF3 57 pegylated interferon alfa 2b 57 carotid stenting 57 Rosuvastatin 57 patients undergoing percutaneous 57 mg dose 57 CAMMS# 57 PRECISE 57 recurrent glioblastoma multiforme 57 Digital Mammographic Imaging 57 Intervention Trial GAIT 57 dosing regimens 57 CYPHER ® Stent 57 multicentre prospective 57 COMFORT II 57 phase Ib clinical 57 ARIXTRA 57 Pivotal Trial 57 MADIT 57 sorafenib Nexavar 57 TAXUS V 57 phase IIb study 57 pharmacokinetic PK 57 dose cohorts 57 ADAGIO study 57 NATRECOR ® 57 BCIRG 57 prospective observational cohort 57 multiple ascending dose 57 efficacy 57 Acute Myocardial Infarction 57 Zilver PTX 57 confirmatory Phase III 57 Phase Ib study 57 safety tolerability pharmacokinetics 57 prospective multicenter study 57 Phase #b/#a 57 antihypertensive therapy 57 sirolimus eluting stents 57 AIR CF2 57 Phase 1a clinical 57 ToGA 57 HYVET 57 Screening Trial 57 Phase 2b kidney transplant 57 PREVENT IV 56 Phase III randomized placebo 56 IMPROVE IT 56 randomized controlled multicenter 56 STICH trial 56 Acute Ischemic Stroke 56 tolerability 56 prospective multicentre 56 Phase III trials 56 bendamustine 56 metastatic RCC 56 fenretinide 56 RIO Lipids 56 TRITON TIMI 56 ROCKET AF 56 generalizability 56 eprotirome 56 elective PCI 56 CURRENT OASIS 7 56 dose escalation phase 56 dosage regimens 56 thorough QT 56 APTIVUS r 56 afatinib 56 iPrEx study 56 oral deforolimus 56 Thrombolysis 56 hypertensive patients 56 GAMMAGARD 56 Prospective Randomized 56 PERSEUS 56 safety tolerability pharmacokinetic 56 valsartan 56 insulin detemir 56 Tryton Side Branch 56 MGd 56 randomized controlled Phase 56 PREZISTA r 56 label multicenter Phase 56 WHI 56 NSTE ACS 56 pharmacokinetic studies 56 warfarin therapy 56 dose regimens 56 pharmacodynamics PD 56 telmisartan 56 CYPHER R Stent 56 cluster randomized controlled 56 n = 56 ConclusionThis 56 nesiritide 56 ENESTnd 56 NEVO ™ 56 TAXUS stent 56 SPIRIT FIRST 56 pharmacodynamic profile 56 EOquin TM 56 CLARITY study 56 CLARITY TIMI 56 superficial bladder cancer 56 Myocardial Infarction Study 56 mycophenolate mofetil 56 bosentan 56 APPRAISE 56 viral kinetics 56 CIMZIA TM certolizumab pegol 56 tanespimycin 56 Phase III placebo controlled 56 pharmacodynamic effects 56 ABSORB clinical 56 Phase 2a 56 sunitinib 56 metreleptin 56 observational cohort study 56 paricalcitol 56 vicriviroc 56 macrovascular disease 56 fosbretabulin 56 rt PA 56 bevacizumab Avastin 56 DU #b 56 Placebo controlled 56 assessing T DM1 56 carotid artery stenting CAS 55 ILLUMINATE 55 axitinib 55 OLYMPIA registry 55 Amrubicin 55 HCV RESPOND 2 55 fallopian tube cancers 55 Phase #/#a 55 SCD HeFT 55 Doxil ® 55 transcatheter aortic valve implantation 55 lacosamide 55 composite endpoint 55 Ophena 55 COPAXONE R 55 PROMUS Element Stent 55 Myocardial Infarction 55 ELCAP 55 TAXUS Liberte Stent 55 AVADO 55 patients undergoing CABG 55 ACCORD Lipid 55 safety tolerability 55 AEGR 55 thrombus aspiration 55 ascending doses 55 Clinical Outcomes Utilizing Revascularization 55 PICSO ® 55 doxorubicin docetaxel 55 relapsed MM 55 EDEMA3 55 glatiramer acetate 55 STEMI patients 55 #mg/day [001] 55 MADIT CRT 55 ENDEAVOR clinical 55 unblinded 55 Multicenter Automatic Defibrillator Implantation 55 pitavastatin 55 bevacizumab 55 blind multicentre 55 rALLy clinical trial 55 tolvaptan 55 acute coronary syndromes ACS 55 CYPHER Stent 55 Prospective Randomized Trial 55 PRADAXA 55 SORT OUT III 55 Heart Failure Trial 55 prucalopride 55 ZACTIMA 55 candesartan cilexetil 55 LEXIVA r 55 bronchial thermoplasty 55 Telmisartan 55 INTERCEPT platelets 55 optimal dosing 55 sirolimus eluting stent 55 tocilizumab 55 CLBP 55 ritonavir boosted 55 AZILECT R 55 lintuzumab 55 HORIZONS AMI 55 ACTEMRA TM 55 Sequenced Treatment Alternatives 55 temsirolimus 55 Phase Ib clinical trials 55 eltrombopag 55 monotherapy 55 acute ischemic stroke 55 Phase III clinical trials 55 pharmacokinetic 55 EORTC 55 PRE SURGE 55 APEX PD 55 Phase Ib IIa clinical 55 PROactive study 55 NATRECOR R 55 Randomized Clinical Trial 55 CALGB # [001] 55 registrational Phase 55 PFO closure 55 pivotal Phase 55 CHAMPION PLATFORM 55 olaparib 55 Aggressive Drug Evaluation 55 cetrorelix 55 ACCORD 55 Phase III metastatic melanoma 55 bioabsorbable stent 55 trabedersen 55 evaluating tivozanib 55 darunavir ritonavir 55 posaconazole 55 CYPHER ® Sirolimus eluting 55 observational cohort 55 refractory CLL 55 ACTEMRA 55 hemodialysis patients 55 Phase III psoriasis 55 NSABP 55 Efficacy 55 pre menopausal 55 enzastaurin 55 oral ridaforolimus 55 treatment naive genotype 55 DCCT 55 aldosterone antagonists 55 antithrombotic therapy 55 Randomized Study 55 AIR2 Trial 55 HIVNET 54 RTOG 54 beta blocker therapy 54 Traficet EN 54 randomized Phase 2b 54 relapsing multiple sclerosis 54 cilostazol 54 recurrent ovarian cancer 54 ONTARGET R 54 teriparatide 54 multicentric 54 Initiated Phase 54 post hoc 54 selenium supplementation 54 Rheos System 54 label multicenter randomized 54 ximelagatran 54 BETAS 54 iPrEx 54 neratinib 54 evaluating REVLIMID 54 ZoMaxx 54 unstable angina UA 54 irbesartan 54 Augment Injectable 54 pharmacodynamic PD 54 alvespimycin 54 noninferior 54 Valsartan 54 MAGE A3 ASCI 54 eluting stent 54 denufosol 54 WHIMS 54 factorial design 54 Multicentre 54 ZYBRESTAT fosbretabulin 54 canakinumab 54 phase III SIMPADICO 54 multidose 54 Cloretazine 54 treatment naïve genotype 54 vorinostat 54 Dabigatran 54 CANCIDAS 54 pharmacokinetic pharmacodynamic 54 International Verapamil SR 54 relapsing remitting MS RRMS 54 TAXUS TM 54 Tavocept 54 UPLIFT 54 folate supplementation 54 satraplatin Phase 54 renal tumors 54 peginterferon alfa 2b 54 renal transplantation 54 controlled dose escalation 54 daily Infergen 54 RE MODEL 54 pertuzumab 54 post menopausal 54 Long Lesion 54 tipranavir 54 icatibant 54 rivaroxaban 54 dosing cohorts 54 ACOSOG Z# 54 radical cystectomy 54 PRIMO CABG 54 randomized #:#:# 54 FIX HF 5 54 Endarterectomy 54 HCV infected 54 rosuvastatin Crestor 54 basal bolus regimen 54 insulin glargine 54 dietary questionnaires 54 ACRIN 54 cohort 54 adjuvant radiotherapy 54 Polyp Prevention Trial 54 Clinical trials 54 Sirolimus eluting Coronary Stent 54 pioglitazone 54 relapsing remitting multiple sclerosis 54 ISAR REACT 54 ataluren 54 crizotinib PF # 54 sipuleucel T 54 Azedra 54 Multiethnic Study 54 CAPRISA 54 ENDEAVOR 54 ancrod 54 nulliparous women 54 AREDS 54 ISAR TEST 54 ASSERT trial 54 Percutaneous Coronary Intervention 54 cinacalcet 54 ibandronate 54 HbA1c levels 54 RoACTEMRA 54 immunomodulatory therapy 54 deferiprone 54 visilizumab 54 angiotensin receptor blocker ARB 54 Clinical Study 54 lomitapide 54 fluvastatin 54 AVOREN 54 etanercept 54 Coronary Stent 54 liver resection 54 LCP Tacro 54 cilengitide 54 carotid endarterectomy CEA 54 Radiation Therapy Oncology 54 lanthanum carbonate 54 metastatic renal cell carcinoma 54 prespecified 54 SCIg 54 boosted protease inhibitor 54 Glucosamine Chondroitin Arthritis 54 Val MARC 54 anti arrhythmic drug 54 Taxotere ® 54 CATIE AD 54 Randomized Phase 54 PLCO 54 pramlintide 54 KRN# 54 antitumor effect 54 LPV r 54 sulodexide 54 pharmacokinetic characteristics 54 Phase IIa trials 54 strontium ranelate 54 hypogonadal men 54 stage IIIB 54 SYNTAX 54 BR.# 54 Edwards SAPIEN valve 54 registrational 54 paclitaxel eluting stent 54 TDF FTC 54 ongoing Phase 1b 54 LibiGel Phase III 54 tesmilifene 54 ENGAGE AF TIMI 54 dose cohort 54 virologic 54 BRAF inhibitor 54 Framingham Offspring Study 54 CLL8 54 CaPSURE 54 neoadjuvant treatment 54 biologic therapy 54 FOSRENOL R 54 Platelet Inhibition 54 azacitidine 54 Phase III Clinical Trial 54 registrational trial 54 CoFactor 54 interferon gamma 1b 54 Group RTOG 54 stable angina 54 DAPT Study 54 recurrent glioma 54 CUSTOM II 54 ANCHOR trial 54 iniparib 53 ORMD 53 DSMB 53 velafermin 53 Sym# 53 pazopanib 53 statin 53 Acute Decompensated Heart Failure 53 unfractionated heparin UFH 53 Stent System 53 CUSTOM III 53 ruboxistaurin 53 efficacy endpoints 53 IFN alfa 53 ARCOXIA 53 Infarct 53 MADIT CRT trial 53 atorvastatin Lipitor 53 ezetimibe simvastatin 53 desvenlafaxine succinate 53 #:# randomization 53 IIa clinical 53 Stenting Trial 53 olmesartan 53 randomized controlled trials RCTs 53 GORE VIABAHN Endoprosthesis 53 CRESTOR #mg 53 pegylated liposomal doxorubicin 53 oral ibandronate 53 Taxotere R 53 ZD# [001] 53 bolus dose 53 RESOLUTE clinical 53 ELACYT 53 BOLDER 53 Phase #b/#a clinical 53 trial evaluating PRX# 53 GEM OS1 53 lixisenatide 53 NEVO 53 cediranib 53 APEX AMI trial 53 antiplatelet therapy 53 Raloxifene Evaluation MORE 53 BENICAR HCT 53 CardioFit 53 Degarelix 53 tecarfarin 53 AZOR 53 thromboprophylaxis 53 goserelin 53 XIENCE V Everolimus Eluting 53 ARBITER 6 53 Zavesca R 53 ABCSG 53 calcium supplementation 53 sorafenib 53 Ophena TM 53 HIV HCV coinfected 53 Combo Stent 53 Evaluation WISE 53 premenopausal women 53 adenoma recurrence 53 colesevelam HCl 53 brivaracetam 53 ganetespib 53 acute coronary syndrome 53 unfractionated heparin 53 galiximab 53 oral Xeloda 53 Communities ARIC Study 53 preoperative chemotherapy 53 nondiabetic patients 53 nonmetastatic prostate cancer 53 severe aortic stenosis 53 FOLPI 53 EVIZON 53 CHARISMA trial 53 Feasibility Trial 53 ixabepilone 53 RG# ITMN 53 Randomized Double Blind Placebo 53 pain palliation 53 PREVAIL 53 ADMIRE HF 53 SYNTAX trial 53 study 53 Meta analyzes 53 histologically confirmed 53 EmbraceAC 53 PIX# [002] 53 STEP BD 53 observer blinded randomized 53 CBLC# 53 efficacy endpoint 53 dyskinesia PD LID 53 Spine Patient Outcomes 53 Bivalirudin 53 ABC/3TC 53 GetGoal Phase III 53 carotid stents 53 JAK inhibitor 53 direct thrombin inhibitor 53 II Clinical Trial 53 Relieve Depression 53 TAXUS Stent 53 subcutaneously administered 53 cortical stimulation 53 label dose titration 53 secondary efficacy endpoints 53 Sibutramine Cardiovascular Outcomes 53 CR# vcMMAE 53 AA Amyloidosis 53 IV NSCLC 53 WallFlex Biliary RX 53 evaluating Actimmune 53 postmenopausal 53 pharmacokinetic PK study 53 GOUT 53 CIMZIA TM 53 HuMax EGFr 53 normotensive 53 PRTX 53 Microplasmin 53 colorectal liver metastases 53 efavirenz EFV 53 decitabine 53 blinded placebo 53 PreCISe 53 tremelimumab 53 RG# [001] 53 protease inhibitor PI 53 vidofludimus 53 β blockers 53 ELONVA 53 noninfectious uveitis 53 REG1 53 adjuvant therapy 53 dosing cohort 53 risperidone Risperdal 53 INTERHEART study 53 Phase III Trial 53 mild gestational diabetes 53 TAXOTERE R 53 Ranolazine 53 cangrelor 53 PERSEUS clinical program 53 PD LID 53 tolerability pharmacokinetics 53 ganaxolone 53 pegaptanib 53 ascending dose study 53 PARTNER Trial 53 Clinical Trial 53 oral anticoagulant 53 Alzheimer Disease Neuroimaging Initiative 53 prostate cancer PCa 53 COPAXONE ® 53 ENDEAVOR II 53 dirucotide MBP# 53 Acute Coronary Syndromes ACS 53 relapsed multiple myeloma 53 randomly assigned 53 retinal vein occlusion induced 53 Dialysis Outcomes 53 epidemiological studies 53 rosiglitazone 53 Onrigin 53 glufosfamide 53 SCH # 53 carboplatin paclitaxel 53 MEND CABG II 53 lipid lowering 53 IMPACT DCM 53 relapsed refractory multiple myeloma 53 platelet inhibitor 53 PREOS 53 randomized placebo 53 Phase #/#a clinical 53 underwent liver transplantation 53 vandetanib 53 XIENCE V stent 53 MICARDIS ® 53 NeuroStar TMS Therapy 53 CALGB # [002] 53 Chronic Heart Failure 53 Study AREDS 53 solifenacin 53 antiplatelet agents 53 Genous stent 53 coronary interventions 53 mixed hyperlipidemia 53 NCT# 53 candesartan 53 EMPHASIS HF trial 53 modified REGENESIS Phase IIb 52 dexpramipexole 52 miglustat 52 dose regimen 52 neoadjuvant chemotherapy 52 CIMZIA ™ 52 REVLIMID lenalidomide 52 Atherosclerosis Risk 52 dose titration 52 thrombolytic therapy 52 glargine 52 transurethral resection 52 XELOX 52 IIa trial 52 #F FDG PET 52 NP2 Enkephalin 52 PROPEL trial 52 SIMPADICO 52 pharmacokinetic parameters 52 heavily pretreated 52 Randomized placebo controlled 52 multicenter clinical trials 52 BoNTA 52 stage IIIb IV 52 CYPHER R stent 52 transplantation HSCT 52 antiplatelet agent 52 varespladib 52 zoledronic acid 52 pimecrolimus cream 52 INCB# [001] 52 SEROQUEL 52 CHARM Added 52 e HEALING 52 coronary revascularization 52 Randomized Controlled Trial 52 Lipid Lowering Treatment 52 androgen suppression 52 Dacogen injection 52 adecatumumab 52 Subgroup analysis 52 oral iron chelator 52 #mg dose [001] 52 designated HVTN 52 paclitaxel poliglumex 52 #mg dose [003] 52 gefitinib Iressa 52 WHEL 52 prostate cancer CRPC 52 XIENCE V demonstrated 52 invasive candidiasis 52 clopidogrel Plavix 52 sirolimus eluting 52 atherogenic dyslipidemia 52 evaluable patients 52 FASLODEX 52 antiepileptic drug 52 glucose lowering 52 arzoxifene 52 Phase III multicenter 52 Patency 52 Phase 2b randomized 52 dose atorvastatin 52 secondary endpoint 52 Endeavor stent 52 forodesine 52 tenofovir gel 52 cardioprotective effects 52 6R BH4 52 biliary tract cancer 52 metaanalysis 52 CA4P 52 Mylotarg 52 daclizumab 52 Torisel 52 oral FTY# 52 chlorambucil 52 Trandolapril 52 MIVI TRUST 52 ERSPC 52 antiarrhythmic drug 52 Ceplene/IL-2 52 Tocilizumab 52 IMA# 52 TYKERB 52 clinical endpoints 52 PEG INTRON 52 intravenous dosing 52 hypercholesterolemia 52 Prospective Multicenter 52 degarelix 52 TRANSFORMS 52 periprocedural MI 52 GISSI 52 anti leukemic 52 comparator arm 52 Peginterferon 52 JANUVIA 52 GRAVITAS trial 52 Prostate AdenoCarcinoma Treatment 52 concurrent chemoradiation 52 QLT# 52 abacavir lamivudine 52 retinal thickness 52 NPH insulin 52 ischemic cardiomyopathy 52 AVANDIA 52 Left Ventricular Dysfunction

Back to home page